Recruiting PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT06530251

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

A Phase Ib/II Study of AK112 in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)

Sponsor: Akeso

Interventions AK112 AK127 AK130 Bevacizumab biosimilar Cadonilimab Sintilimab Injection

Updated 4 times since 2024 Last updated: Mar 2, 2026 Started: Sep 24, 2024 Primary completion: Jun 30, 2026 Completion: Sep 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Hepatocellular Carcinoma, this trial is actively recruiting participants. The trial is conducted by Akeso and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Mar 2026 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China
• Jinan, China